Generics drive Amerisource financials; Facilities planned, completed and approved;

> Big 3 drug distributor Amerisource cites sales of generics as a driver in its higher-than-expected quarterly profit growth. Article

> The FDA has approved Orthovita's facility in Malvern, PA, for collagen processing and the manufacture of collagen-based products. Article

> Novavax has been issued U.S. Patent No. 7,763,450, "Functional Influenza Virus-Like Particles (VLPS)," for the manufacturing process that uses influenza gene sequences for production of vaccines to protect against current and future seasonal and pandemic flu strains. Release

> Meridian Life Science is boosting investment in facilities, equipment and infrastructure to provide R&D support for contract manufacturing and custom biologics development. Release

> ATMI has completed the expansion of its Bloomington, MN, manufacturing facility, the North American hub for production and development of the Integrity single-use technology products. Announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.